Pasithea Therapeutics (KTTAW) Competitors $0.02 0.00 (-17.28%) As of 05/2/2025 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock KTTAW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity Pasithea Therapeutics (NASDAQ:KTTAW) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations. Which has better valuation and earnings, KTTAW or ATNFW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea Therapeutics$486.56KN/AN/AN/AN/A180 Life SciencesN/AN/AN/AN/AN/A Does the MarketBeat Community favor KTTAW or ATNFW? Pasithea Therapeutics and 180 Life Sciences both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformPasithea TherapeuticsN/AN/A180 Life SciencesN/AN/A Does the media prefer KTTAW or ATNFW? In the previous week, 180 Life Sciences had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Pasithea Therapeutics. 180 Life Sciences' average media sentiment score of 0.59 beat Pasithea Therapeutics' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Pasithea Therapeutics Neutral 180 Life Sciences Positive Is KTTAW or ATNFW more profitable? Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A N/A N/A 180 Life Sciences N/A N/A N/A Summary180 Life Sciences beats Pasithea Therapeutics on 2 of the 3 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTAW vs. The Competition Export to ExcelMetricPasithea TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$125.57M$5.56B$8.03BDividend YieldN/A3.69%5.36%4.22%P/E RatioN/A3.2722.7918.88Price / SalesN/A4,272.58406.35106.93Price / CashN/A13.0238.1834.62Price / BookN/A34.206.794.34Net IncomeN/A-$90.45M$3.23B$248.14M7 Day PerformanceN/A1.33%3.36%3.18%1 Month PerformanceN/A7.35%11.23%13.07%1 Year PerformanceN/A94.88%16.78%5.08% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAWPasithea TherapeuticsN/A$0.02-17.3%N/A+60.7%$0.00$486,559.000.003Gap DownATNFW180 Life SciencesN/A$0.01flatN/A-14.1%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/A-86.4%$0.00N/A0.002AIMDWAinosN/A$0.10-5.9%N/A+39.0%$0.00$20,729.000.0040Gap UpALVOWAlvotechN/A$1.32+3.1%N/AN/A$0.00$489.68M0.004Short Interest ↑News CoverageGap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02-20.5%N/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.04-13.1%N/A-33.3%$0.00$37.32M0.0070Gap DownBTMDWbioteN/A$0.02-5.1%N/A-85.3%$0.00$197.19M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.12+8.0%N/A-86.7%$0.00N/A0.008Gap UpCELUWCelularityN/A$0.04-10.1%N/A+100.0%$0.00$48.20M0.00220Positive NewsGap Up Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Celularity Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTAW) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredWhy Elon put $51 million into thisWhile fear dominates the headlines, a silent breakthrough could turn panic into profit. The future of AI fa...True Market Insiders | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KTTAW Stock Free KTTAW Stock Alerts